公开(公告)号：US11072644B2

公开(公告)日：2021-07-27

申请号：US15525906

申请日：2015-11-09

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind Rajpal ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US20210079412A1

公开(公告)日：2021-03-18

申请号：US17052351

申请日：2019-05-02

Applicant: CELLECTIS

Inventor： Nicholas BALTES ,  Javier GIL HUMANES

IPC: C12N15/82 ,  C12N9/16

Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).

公开(公告)号：US20210060079A1

公开(公告)日：2021-03-04

申请号：US17099608

申请日：2020-11-16

Applicant: Cellectis

Inventor： Roman GALETTO ,  Julianne SMITH ,  Andrew SCHARENBERG ,  Cécile SCHIFFER-MANNIOUI

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.

公开(公告)号：US20200277625A1

公开(公告)日：2020-09-03

申请号：US16793896

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  A61K35/17 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US10759868B2

公开(公告)日：2020-09-01

申请号：US15506643

申请日：2015-09-03

Applicant: CELLECTIS

Inventor： Cècile Schiffer-Mannioui

IPC: C07K16/30 ,  C07K14/735 ,  C07K14/705 ,  C07K14/725 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

公开(公告)号：US10738289B2

公开(公告)日：2020-08-11

申请号：US15466714

申请日：2017-03-22

Applicant: CELLECTIS S.A.

Inventor： George Silva ,  Marine Beurdeley

IPC: C12N9/22 ,  C07K14/47 ,  C12N9/16 ,  C12N15/90 ,  C12N15/82 ,  C07K14/195

Abstract: The present invention relates to a method to cleave target nucleic acid sequence by the catalytic domain of a GIY-YIG homing endonucleases I-TevI. More precisely, the invention relates to the deciphering of new preferential I-TevI cleavage sites for efficient and specific cleavage activity. The invention concerns a method for the generation of TevI specific chimeric endonucleases to target nucleic acid sequence including such cleavage sites and methods of using same for gene editing.

公开(公告)号：US20200224163A1

公开(公告)日：2020-07-16

申请号：US16340222

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N15/90 ,  C12N9/22

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20200208174A1

公开(公告)日：2020-07-02

申请号：US16314697

申请日：2017-06-30

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N13/00 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient,for their subsequent use in therapeutic treatments.

公开(公告)号：US20200080073A1

公开(公告)日：2020-03-12

申请号：US16655228

申请日：2019-10-17

Applicant: CELLECTIS S. A.

Inventor： Alan D. King ,  Richard E. Walters ,  Stephen B. Deitz ,  Donald J. Rodis ,  Derin C. Walters

IPC: C12N13/00 ,  C12M1/42

Abstract: An electroporation apparatus and its novel chamber with inlet ports for mixing cells and exogenous material. The inlet ports are oriented in nonparallel to each other immediately adjacent at the same top comer of the first wall of the chamber. The mixing chamber comprises successive wall sections, two curved walls at its bottom; the first curved comer is on the same side of the chamber where the liquids enter the chamber, and directs the liquids to the second curved comer at the opposing side of the chamber, which in turn further redirects the mixing to the first curved corner. The direction of the liquid flow mixture change direction at least twice into the mixing chamber.

公开(公告)号：US10584352B2

公开(公告)日：2020-03-10

申请号：US15891496

申请日：2018-02-08

Applicant: Cellectis

Inventor： Philippe Duchateau ,  André Choulika ,  Laurent Poirot

IPC: A61K35/17 ,  C12N15/85 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90 ,  C12N15/113

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.